Biotechnology

Evaxion A/S

Evaxion A/S released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5 (forecast USD -0.01)

Evaxion A/S to Release FY2026 Q1 Earnings on May 7 Pre-Market (EST), Forecast Revenue USD 0, EPS USD -0.01

Evaxion A/S released FY2025 Q4 earnings on March 5 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7195 (forecast USD -0.01)

Evaxion A/S released FY2025 earnings on March 5 Pre-Market (EST), actual revenue USD 7.528 M (forecast USD 7.51 M), actual EPS USD -1 (forecast USD -0.025)

Evaxion A/S to Release FY2025 Earnings on March 5, Pre-Market EST; Forecast Revenue USD 7.51 M, EPS USD -0.02

Evaxion A/S Expanding AI-Immunology Platform

Evaxion A/S presents preclinical data for its AML vaccine candidate EVX-04

Evaxion A/S Presents New Findings of Personalized Cancer Vaccine at the SITC Annual Meeting

Lake Street Maintains Buy Rating on Evaxion Biotech with a $11 Target Price

Evaxion A/S released FY2025 9 Months earnings on November 6, Pre-Market EST, actual revenue USD 7.529M, actual EPS USD -0.5599

Evaxion A/S released FY2025 Q3 earnings on November 6 Pre-Market EST, actual revenue USD 7.492 M (forecast USD 2.5 M), actual EPS USD 0.726 (forecast USD -0.01)

Evaxion A/S's Cancer Vaccine EVX-04 Shows Promising Preclinical Results in AML Treatment

Evaxion A/S to Release FY2025 Q3 Earnings on November 6, Pre-Market EST; Forecast Revenue USD 7.5 M, EPS USD -0.59

Evaxion Biotech Receives 'Buy' Rating From Soumit Roy With A Price Target Of $10

Evaxion Reports 75% Objective Response Rate in Personalized Cancer Vaccine Phase 2 Trial

Evaxion A/S to present personalized cancer vaccine phase II data at ESMO

Evaxion A/S Upgrades Its AI-Immunology™ Platform

Evaxion A/S to Present New Data on Personalized Cancer Vaccine EVX-01 at SITC 2025 Annual Meeting

Evaxion A/S released FY2025 Q2 earnings on August 14 Pre-Market (EST), actual revenue USD 37K (forecast USD 0), actual EPS USD -1 (forecast USD -0.58)

Evaxion A/S released FY2025 Semi-Annual Earnings on August 14 Pre-Market EST, Actual Revenue USD 37K, Actual EPS USD -1.5

NextNRG

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

InMed Pharmaceuticals

Meiwu Tech

Amesite

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

CN Energy

Generation Income Properties

MetaVia

Co-Diagnostics

BNTX

DBVT

EVAX

TRIB

European equities traded in the US as American depositary receipts rose 0.88% to 1,825.10 on the S&P Europe Select ADR Index. Notable gainers included Evaxion (+4.6%) and Royal Philips (+2.9%), while decliners included DBV Technologies (-3.2%) and BioNTech (-2%). UK gainers were led by Autolus Therapeutics (+16%) and Trinity Biotech (+6.2%), with NuCana (-8.3%) and Biodexa Pharmaceuticals (-3%) among the decliners.

fidelity

BioNTech SE

DBV Tech

Trinity Biotech

Koninklijke Philips Elect

Criteo SA

GRIFOLS SA

Nokia Oyj

Ascendis Pharmac

Autolus Therapeutics

WPP Plc

Pearson

Pearson PLC

Nucana

Biodexa Pharmaceuticals

Amarin

Mereo Biopharma

Koninklijke Philips N.V.

European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading

AKTX

EDAP

MREO

European equities traded in the US as American depositary receipts saw a slight increase of 0.08% to 1,829.64 on the S&P Europe Select ADR Index. Notable gainers included Nokia (up 4.1%) and Evaxion (up 3.9%), while SAP and EDAP TMS led the decliners with drops of 4.8% and 4.7%, respectively. In the UK, Akari Therapeutics rose 11%, while Mereo BioPharma Group fell 3.1%.

Fidelity

Akari Therap

EDAP TMS

SAP SE

Trivago NV

SAP AG-Sponsored

Natuzzi SPA

 BHP Group Ltd

Vodafone 

Vodafone Group Plc

Endava

BHP Group Limited

BHP Group Plc

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress | EVAX Stock News

StockTitan

First Trust NYSE Arca Biotech Index Fd

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress | EVAX Stock News

Maxim Group analyst Michael Okunewitch has initiated a Buy rating on Evaxion (EVAX), citing strong clinical data, an AI-driven vaccine platform, and a cash runway extending to the second half of 2027. He highlights promising results from recent AACR presentations and the company's partnerships with major players like Merck and the Gates Foundation. Lake Street also maintains a Buy rating with a $9.00 price target. However, EVAX's stock has seen a 36.21% decline over the past six months, dropping from $6.38 to $4.07.

Tip Ranks

Merck

Michael Okunewitch Initiates Buy on Evaxion, Citing Strong Clinical Data, AI-Driven Vaccine Platform, and Cash Runway to 2H 2027

SAPH

SPEU

European equities traded in the US saw a rise in American depositary receipts, increasing 0.78% to 1,826.25 on the S&P Europe Select ADR Index, up 1.3% for the week. Notable gainers included Nokia (4.7%) and Evaxion (4.4%), while SAP (-1.6%) and Sequans Communications (-1.2%) were among the decliners. In the UK, Lloyds Banking Group rose 3%, while Biodexa Pharmaceuticals fell 4.9%.

SAP SE ADRhedged

SPDR Portfolio Europe ETF

European Equities Traded in the US as American Depositary Receipts Rise Friday

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

nasdaq

Nasdaq

Evaxion (EVAX) Q1 2026 Earnings Transcript

Evaxion Biotech received a Buy rating from analyst Debanjana Chatterjee of JonesTrading, maintaining a $10 price target. The rating is based on the company's AI-enabled cancer vaccine platform and upcoming catalysts, including pivotal data for EVX-01 in melanoma. Chatterjee notes strong T-cell responses and a high rate of selected neoantigens, indicating best-in-class potential. He also highlights upcoming events that could enhance Evaxion's value, alongside a manageable cash burn, suggesting an attractive risk-reward profile. H.C. Wainwright also reiterated a Buy rating with a $16 price target.

Evaxion: Buy Rating Reiterated on AI Cancer Vaccine Platform and Upcoming Catalysts; $10 Price Target Unchanged

Evaxion A/S received shareholder approval for expanded financing powers at its Annual General Meeting on April 16, 2026. Shareholders approved the 2025 audited annual report, re-elected four directors, and appointed a new board member. Amendments to the Articles of Association allow the company to issue up to DKK 11.9 million in warrants and raise DKK 73.5 million via convertible loan notes, enhancing financial flexibility but risking share dilution. Analysts rate EVAX stock as a Buy with a $9.00 price target, though concerns about cash generation and profitability persist.

Evaxion A/S Wins Shareholder Approval for Expanded Equity and Convertible Financing Powers

Evaxion A/S(EVAX.US)

European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress | EVAX Stock News

Michael Okunewitch Initiates Buy on Evaxion, Citing Strong Clinical Data, AI-Driven Vaccine Platform, and Cash Runway to 2H 2027

European Equities Traded in the US as American Depositary Receipts Rise Friday

Evaxion (EVAX) Q1 2026 Earnings Transcript

Evaxion: Buy Rating Reiterated on AI Cancer Vaccine Platform and Upcoming Catalysts; $10 Price Target Unchanged

Evaxion A/S Wins Shareholder Approval for Expanded Equity and Convertible Financing Powers